Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Apnimed, a late-stage clinical pharmaceutical company focused on sleep-related breathing diseases, announced Q2 2026 financial results, highlighting FDA acceptance of the NDA for AD109 (Oxnimbi), an oral therapy targeting obstructive sleep apnea (OSA), with an FDA decision expected by February 28, 2027. The company completed a successful IPO, raisi…